Movement Alert｜Abivax S.A. Falls 5.07% in Regular Trading, H1 miss and target cuts remain an overhang

Market Focus10-17

On October 17, Abivax S.A. fell 5.07% in Regular Trading, trading at $87.7338, with turnover of $51.9823 million.

The move aligns with lingering pressure from the company’s latest H1 results and subsequent analyst target reductions. Abivax reported EPS of $(2.43), materially worse than the $(1.08) consensus estimate, while sales of $2.959 million exceeded the $1.860 million estimate. After the release, Wedbush cut its price target to $118 from $160 and kept a Neutral rating, while Truist also lowered its target. The stock’s core value driver remains obefazimod, which is in Phase 3 development for moderately to severely active ulcerative colitis, with the market still focused on regulatory filing timing and commercialization prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment